The company's investment objective is to seek capital appreciation through investment in a diversified portfolio of shares and related securities in biotechnology companies across the world. It has strict investment guidelines, including not investing more than 15% of the value of its gross assets in other closed-ended investment companies listed on the London Stock Exchange, not investing more than 15% of the value of its gross assets in any one individual stock at the time of acquisition, and not investing more than 10% of the value of its gross assets in direct unquoted investments at the time of acquisition. Its portfolio manager is OrbiMed Capital LLC, and its alternative investment fund manager is Frostrow Capital LLP.